Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US-9533988-B2 · Jan 3, 2017 · US
Inhibitors of the fibroblast growth factor receptor
US10196436B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10196436-B2 |
| Application number | US-201815867637-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 10, 2018 |
| Priority date | Jul 11, 2012 |
| Publication date | Feb 5, 2019 |
| Grant date | Feb 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
First claim
Opening claim text (preview).
We claim: 1. A compound which is:
Assignees
Inventors
Classifications
Antihyperlipidemics · CPC title
Antineoplastic agents · CPC title
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title
Drugs for disorders of the nervous system · CPC title
- A61K31/4375Primary
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10196436B2 cover?
- Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
- Who is the assignee on this patent?
- Blueprint Medicines Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4375. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).